U.S. markets open in 1 hour 47 minutes

Aravive, Inc. (ARAV)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
4.9400-0.1700 (-3.33%)
At close: 4:00PM EDT
Sign in to post a message.
  • D
    Dan
    Any Catalyst in particular we're waiting on?
    Bullish
  • Y
    Yahoo Finance Insights
    Aravive is down 10.11% to 5.60
  • Y
    Yahoo Finance Insights
    Aravive is up 10.48% to 6.22
  • D
    David
    Will hold long term should be good , loading up on ORN,RVP AND SQNS, STM
  • Y
    Yahoo Finance Insights
    Aravive is up 9.45% to 5.56
  • K
    K
    This is acting like a slow death (lost almost 50% in 3 weeks).
  • B
    Brutal Bacon
    If anyone is awake on this board, this looks to be the deal of the day under $10! I’m in at $9.60
    Bullish
  • c
    christian
    what's happening here,going bearish day by day,please any negative news to it?
    Bearish
  • Y
    Yahoo Finance Insights
    Aravive is up 12.97% to 6.72
  • Y
    Yahoo Finance Insights
    Aravive is down 12.22% to 9.12
  • p
    p
    New presentations on the corporate site.
  • p
    p
    Compare this with TCRR that also just completed a Phase 1 study. In a subgroup analysis of patients who had not been previously exposed to bevacizumab in their prior lines of therapy, Aravive’s AVB-500 yielded an Overall Response Rate of 60% (6/10 including 2 Complete Responses) when combined with PAC. TCRR reported their ORR was 40% with 2 unconfirmed PRs. Of course these were both safety studies, but in my opinion, it looks like AVB-500 has a lot of potential.
  • s
    sumeet
    The share value is dropping should I keep or sell. Any information will be appreciated. Thanks.
  • J
    Jaudio
    Was there any news at all? I don't get it, why this one so beat up? I think I might want to jump in this one when the hourly trend start to change.
  • n
    nedal
    Why this is down down from $12
  • p
    p
    Sounds like it has a lot of potential when used with PAC ...

    -- In a subgroup analysis of patients who had not been previously exposed to bevacizumab in their prior lines of therapy, AVB-500 yielded an ORR of 60% (6/10 including 2 CR) when combined with PAC and an ORR of 19% (3/16) when combined with PLD. For reference, control arms of the third-party AURELIA Trial of bevacizumab (NCT00976911) showed ORR of 30.2% (out of 55 patients total) with PAC alone and 7.8% (out of 64 patients total) with PLD alone.
  • z
    zhengyu
    It is quite interesting some guys are pumping the shares to get the price down. If you look at the phase 1B data, it looks very promising especially if we exclude those 4 persons at the high dose.
    Bullish
  • r
    rosette
    Where there is smoke there is fire
  • d
    dakdan
    yes it does have potential but remember this is only a phase 1 Study still years out before FDA approval